Modality
Multispecific
MOA
USP1i
Target
PARP
Pathway
NF-κB
SLEUrothelial Ca
Development Pipeline
Preclinical
~Oct 2016
→ ~Jan 2018
Phase 1
~Apr 2018
→ ~Jul 2019
Phase 2
~Oct 2019
→ ~Jan 2021
Phase 3
Apr 2021
→ Apr 2030
Phase 3Current
NCT04795362
2,782 pts·SLE
2021-04→2030-04·Not yet recruiting
2,782 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-04-114.0y awayPh3 Readout· SLE
Trial Timeline
Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2
P3
Not yet…
Catalysts
Ph3 Readout
2030-04-11 · 4.0y away
SLE
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04795362 | Phase 3 | SLE | Not yet recr... | 2782 | PFS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Miriosocimab | Pfizer | Phase 1 | PARP | |
| SNY-2934 | Sanofi | Phase 3 | KRASG12D | |
| NVO-2974 | Novo Nordisk | NDA/BLA | PARP | |
| AMG-9052 | Amgen | Phase 2/3 | CDK2 | |
| Semainavolisib | Gilead Sciences | Phase 2 | PARP | |
| Datozumab | Regeneron | Phase 1 | B7-H3 | |
| REG-861 | Regeneron | Phase 2 | PARP | |
| GMA-729 | Genmab | Phase 2 | BCL-2 | |
| Pexanaritide | Innovent Bio | Preclinical | SGLT2 | |
| ROI-9675 | Roivant Sciences | NDA/BLA | HER2 |